Letter to the editor [1]

Radiotherapy and Oncology

Volumn 58, Issue 1, 2001, Pages 89-90

  Ball, David L ^a   Peters, Lester J ^a   Smith, Jennifer ^b  

^a Department of Radiation Oncology ^*  (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; PLATINUM; ANTINEOPLASTIC AGENT;

AUSTRALIA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; HUMAN; LETTER; LUNG NON SMALL CELL CANCER; META ANALYSIS; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE FRACTIONATION; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; LUNG TUMOR; NOTE; RANDOMIZED CONTROLLED TRIAL;

ANTINEOPLASTIC AGENTS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; HUMANS; LUNG NEOPLASMS; RANDOMIZED CONTROLLED TRIALS;

EID: 0035915765     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-8140(00)00305-4     Document Type: Letter

References (6)

1. Updated data for CHART in NSCLC: A missed opportunity
2. Updated data for CHART in NSCLC: Further analyses
3. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials
4. Continuous, hyperfractionated, accelerated radiotherapy (CHART) vs conventional radiotherapy in non-small cell lung cancer: Mature data from the randomised multicentre trial
5. A randomised phase III study of accelerated or standard fraction radiotherapy with or without carboplatin in inoperable non-small cell lung cancer: Final report of an Australian multi-centre trial
6. Effect of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer